那时花开

盘前暴跌！美股大牛股利空突袭！“AI交易”全线下挫_我的网站

一 |     　　美股大牛股突然遭遇猛烈抛售。    Sputnik spoke with Dr. D. B. Bhaaskara, CEO of the multinational company Roerich Healthcare, about the current state of pharma trade with Russia.,Sputnik: Can you explain the current state of pharma supplies to Russia?,D. B. Bhaaskara: Currently, pharmaceutical shipments of Indian firms to Russia are at the same level even after the sanctions. But, there are many proposals (supplies) that Russians are not getting from the European Union. Russians are looking for these materials (chemicals, excipients, APIs [Active Pharmaceutical Ingredients]) with several Indian manufacturers. They have to develop links with Indian firms. There are many proposals from Russia - these proposals are under consideration from the Indian side.,Sputnik: There were reports of delayed payments from Russia initially after sanctions. As we see, trade has jumped manifold in the energy and fertilizer sectors. Do you think payment issues have been resolved in other sectors as well?,D. B. Bhaaskara: Several Indian companies have signed contracts in yuan, which means they are ready to receive payment in China's yuan. Still, the preferred mode of settlement is in the Indian rupee. As export procedures closed successfully in USD/euro/INR, Russians set aside yuan contracts.,My company is receiving regular payment without any delay in Indian rupees or USD or sometimes in euros.,Sputnik: What about logistical issues, as sanctions hit the shipping sector?,D. B. Bhaaskara: The logistical issues are still there because few airlines — namely Aeroflot, Emirates, Qatar, and Turkish — are available for transportation. Transportation costs are slightly high because of no regular cargo consignments. They vary between $8-12 per kg compared to $5 per kg in a normal situation.,Cargo sea shipment is still in a mess. The only port in Gujarat accepts Russian shipping. Here again, the container price is very, very high. We have to pay anything between $9,000 - 12,000 for a container. When there was no conflict or sanctions, it was $2,500 per container.,We have tried to send our shipments via Iran. So, from Gujarat port, the shipment reaches an Iranian port, and from there, it goes via road or rail to Moscow. But, it is taking a much longer time. In general, it is supposed to arrive in 30-40 days, but on an experimental basis, some companies sent their materials via the Iran route, [and they are] still on their way even after two months.,Shanghai is very crowded and has also been hit by the pandemic, making it unsuitable for us. So, the only problem right now is logistics; there is no payment issue.,Some Russian companies have an account with European banks operating in Russia dealing in oil and gas payments. Those banks are being used to send money anywhere worldwide, even with sanctions.,Sputnik: Western firms intended to withdraw their operations in Russia in response to Moscow's special military operation. Do you see some significant investments from Indian pharma companies in Russia to fill the vacuum created by the west?,D. B. Bhaaskara: There are long-pending proposals from a couple of governors, such as [in] Volgograd and Kazan, inviting India's major pharma companies to set up manufacturing units in their region. But, due to the pandemic, nothing moved ahead.,A delegation will be going to Russia to explore the opportunities in Russia in July. A few Indian companies, such as Sun Pharma and Advance Pharma, have manufacturing units in Russia doing finished formulations.,Hopefully, some new companies are interested in setting up units there now. But, Russia is looking to scale up raw material manufacturing, e.g., API. For this, much homework related to regulation should be done between the two governments, especially under sanctions.,Also, big companies such as Sun Pharma, Aurbindo, and Dr. Reddy, all with significant exposure to the US market, may try to avoid investing in Russia because they are scared of the risk associated with sanctions.,Medium-scale companies can come forward to set up raw material (API) manufacturing in Russia. However, it is unclear whether Indian workers/professionals can go and work in Russia. Setting up a new unit in unknown topography with a different language and culture is a little complicated. A lot of these questions are unanswered.。

二 |
　　今日（8月24日），在美股盘前交易中，美股光通信大牛股应用光电（AAOI）股价大幅跳水，一度暴跌超14%。消息面上，应用光电计划通过股票增发融资6亿美元，投资者担忧股权将进一步被稀释，尤其应用光电今年已多次通过同类融资工具募资。

三 | 截至上周五收盘，应用光电股价年内累计涨幅超258%。

四 | 　　与此同时，美股光通信、存储概念股全线走低，当前市场对AI（人工智能）投资可持续性的质疑正在升温，硬件成本的快速攀升令科技企业的AI支出回报率前景蒙上阴影。　　光通信大牛股暴跌　　北京时间8月24日，在美股盘前交易中，应用光电（Applied Optoelectronics）股价直线大跳水，一度暴跌超14%，截至18:00，跌幅达12.4%。　　消息面上，应用光电计划通过“按市价发行”(ATM)方式筹集6亿美元资金，引发市场对其未来现金流紧张的担忧情绪。　　截至今年6月末，应用光电已经累计募资金额达到10.5亿美元，合计售出近780万股股票。其中包括，4月完成的5亿美元ATM融资计划，之后又于5月推出了另一笔6亿美元融资。因此，在投资者已经承受本年度大规模股权稀释之后，最新提交的备案文件意味着，该公司即将开启又一轮大规模股票增发。　　有华尔街交易员指出，短期内股权稀释肯定不是好事。但如果需求旺盛，产能才是真正的瓶颈，那么筹集资金扩大生产或许是公司应该做的。

五 | 　　据悉，应用光电募集的资金主要用于业务快速扩张。

六 | 今年早些时候，公司宣布计划扩建位于得克萨斯州皮尔兰的生产基地，新增厂房面积近40万平方英尺，用于增产AI基础设施所用的800G、1.6T光模块。

七 | 　　根据应用光电此前发布的财报，公司第二季度营收同比增长86%，达到1.919亿美元，环比增长27%。其中，数据中心销售额为1.077亿美元，同比大幅增长140%。　　应用光电管理层在电话会议上表示，AI（人工智能）基础设施相关需求依然强劲，客户需求较公司的供应能力高出约20%至40%。　　应用光电首席执行官 Thompson Lin 将第二季度描述为“关键季度”，预计市场需求至少在2027年年中之前将超过公司产能。　　目前应用光电正在大幅提高资本投入力度。

八 | 财报显示，第二季度资本投入达到5.655亿美元，重点投向400G、800G和1.6T收发器制造能力。　　应用光电表示，2026年下半年，公司的资本开支强度预计高于上半年，资金将来自现有现金、经营现金流、部分股权融资和新增债务。　　截至二季度末，应用光电800G和1.6T产品的合计月产能接近20万只。公司计划到2026年底将相关月产能提升至65万只以上，到2027年底进一步提高至93万只以上。这意味着，应用光电在未来一段时间内，资本开支仍将维持高位，或将进一步加剧公司现金流的紧张程度。　　美股“AI交易”下挫　　与此同时，美股其他光通信概念股盘前普跌，截至北京时间18:00，Coherent、Lumentum跌超4%，迈威尔科技、康宁跌超3%。　　存储芯片概念股亦集体走低，闪迪跌超4%，美光科技、希捷科技跌超3%，SK海力士ADR、西部数据跌超2%。　　在亚太交易时段，日韩股市全线收跌，日经225指数跌0.74%，铠侠大跌超6%，软银集团大跌超5%，爱德万测试跌超3%。韩国KOSPI指数收跌3.12%，三星电子大跌超8%，SK海力士跌超3%。

九 | 　　摩根大通分析师Jay Kwon表示，三星电子的股东回报方案“未能带来积极惊喜”，令市场失望。　　Jay Kwon在最新发布的报告中列出了令市场失望的三项具体内容：第三季度承诺的回报金额、未宣布任何股份回购计划，以及股东回报比例维持在累计自由现金流50%的水平不变。　　Kwon表示：“目前仍不清楚三星电子管理层为何选择分红而非回购，因为我们认为许多投资者更倾向于回购，认为这是更有效的回报方式。”在市场普遍预期三星电子将推出更具力度的资本回报举措的背景下，此次方案的保守程度令投资者措手不及。　　此外，方案中大量细节被推迟至明年1月才最终敲定，亦增加了市场的不确定性，削弱了投资者对公司资本配置意愿的信心。　　当前市场对AI投资可持续性的质疑正在升温。硬件成本的快速攀升令科技企业的AI支出回报率前景蒙上阴影，市场的关注点逐渐从“建设AI基础设施”转向“AI能否产生可量化的商业回报”。

十 | 　　汇丰资产管理亚洲股票高级投资专家Beth Wong表示，投资者不一定只关注AI的建设本身，还在关注企业能否在货币化路线图和投资回报方面保持足够的纪律性。　　根据日程安排，全球“AI总龙头”英伟达将于周三美股盘后公布2027财年第二季度财报，其业绩与业绩指引将直接影响市场对今年AI行情能否延续的判断。　　高盛分析师认为，英伟达大概率会交出超预期的财报与业绩指引，但除非英伟达抛出重磅新利好，否则财报发布后，英伟达股价更有可能出现下跌，而非大幅冲高。

十一 | （文章来源：券商中国）。

Current article:http://uip.ruwentaqintiaozhupapaigai.shop/news/20260826_738.html

Published on:22:48:58